CD274 and neoplasm: These findings highlight the dynamic interplay between radiation-induced immune responses, adaptive resistance mediated by PD-L1 upregulation, and the potential of anti-PD-L1 therapy to reinvigorate TILs and sustain anti-tumor immunity.